Alain Tremblay
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Alain Tremblay has a total of 322 co-authors. Here are the top co-authors by number of shared publications:
Paul MacEachern
Department of Medicine, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada
21 shared publicationsNiloofar Taghizadeh
Department of Emergency Medicine, Cumming School of Medicine, University of Calgary and Emergency Strategic Clinical Network, Alberta Health Services, Calgary, Alberta, Canada
10 shared publicationsDavid R. Stather
Division of Respiratory Medicine, University of Calgary, Calgary, AB, Canada
9 shared publicationsElaine Dumoulin
Department of Medicine, Division of Respirology, University of Calgary, Calgary, AB
7 shared publicationsHuiming Yang
Alberta Health Services, Provincial Population and Public Health, Alberta, Canada
7 shared publicationsAlex Chee
Harvard Medical School, Boston, MA
6 shared publications
Latest Publications
- 6 November 2026
- Published by Elsevier in Journal of Thoracic Oncology
- Vol. 21 (11)
Cytisine for Smoking Cessation in Lung Cancer Screening Participants: Promise, Caveats, and a Path Forward
- 6 November 2026
- Published by Elsevier in Journal of Thoracic Oncology
- Vol. 21 (11)
Cytisine for Smoking Cessation in Lung Cancer Screening Participants: Promise, Caveats, and a Path Forward
- Open Access
- 13 October 2026
- Published by Elsevier in Clinical Lung Cancer
- Vol. 27 (10) , 74-82
Risk of Developing a Subsequent Primary Lung Cancer Among Adult Non-Lung Cancer Survivors: Implications for Lung Cancer Screening and Supportive Care
- 13 October 2026
- Published by Elsevier in Clinical Lung Cancer
- Vol. 27 (10) , 74-82
Open AccessRisk of Developing a Subsequent Primary Lung Cancer Among Adult Non-Lung Cancer Survivors: Implications for Lung Cancer Screening and Supportive Care
- Open Access
- 1 September 2026
- Published by SAGE Publications in Cancer Control
- Vol. 33
Temporal Trends in Lung Cancer Mortality Across 48 Countries from 1950 to 2019: An Ecological Study
Background: The widespread success of tobacco control policy and smoking cessation campaigns has led to considerable reductions in lung cancer mortality. However, it is currently not known how many more deaths might have occurred if not for the substantial progress made in lung cancer control. Methods: In this retrospective study, we used age-specific population counts and lung cancer mortality rates from 1950 to 2019 (from 48 countries) from the Global Cancer Observatory. We estimated age-standardized mortality rates (ASMR), standardized to the WHO (2000-2025) Standard Population. Peak mortality was defined as the year when the maximum ASMR was reached for each country and sex. For each year in the period following peak mortality, the expected number of lung cancer deaths was estimated using peak-year age-specific mortality rates and age-specific population counts for that year. The number of avoided deaths was estimated as the difference between expected and observed lung cancer deaths in that period. Results: Lung cancer mortality peaked for males in all 48 countries but has yet to peak for females in 11 countries. There have been 3.08 million avoided lung cancer deaths since mortality rates peaked for many countries (2.93 million for males, 0.15 million for females). Across these countries, 21.4% and 4.3% of expected lung cancer mortality has been avoided since mortality peaked for males and females, respectively. Fourteen countries have reduced lung cancer mortality more than 25% for men, while only two countries have for women. There have been statistically significant reductions in lung cancer deaths for 46 out of 48 (96%) countries for men and 14 out of 48 (29%) countries for women. Conclusion: There has been a substantial number of lung cancer deaths avoided since mortality rates peaked for many countries, though the reduction in mortality has not been observed in all countries or equally for males and females.
- 1 September 2026
- Published by SAGE Publications in Cancer Control
- Vol. 33
Open AccessTemporal Trends in Lung Cancer Mortality Across 48 Countries from 1950 to 2019: An Ecological Study
Background: The widespread success of tobacco control policy and smoking cessation campaigns has led to considerable reductions in lung cancer mortality. However, it is currently not known how many more deaths might have occurred if not for the substantial progress made in lung cancer control. Methods: In this retrospective study, we used age-specific population counts and lung cancer mortality rates from 1950 to 2019 (from 48 countries) from the Global Cancer Observatory. We estimated age-standardized mortality rates (ASMR), standardized to the WHO (2000-2025) Standard Population. Peak mortality was defined as the year when the maximum ASMR was reached for each country and sex. For each year in the period following peak mortality, the expected number of lung cancer deaths was estimated using peak-year age-specific mortality rates and age-specific population counts for that year. The number of avoided deaths was estimated as the difference between expected and observed lung cancer deaths in that period. Results: Lung cancer mortality peaked for males in all 48 countries but has yet to peak for females in 11 countries. There have been 3.08 million avoided lung cancer deaths since mortality rates peaked for many countries (2.93 million for males, 0.15 million for females). Across these countries, 21.4% and 4.3% of expected lung cancer mortality has been avoided since mortality peaked for males and females, respectively. Fourteen countries have reduced lung cancer mortality more than 25% for men, while only two countries have for women. There have been statistically significant reductions in lung cancer deaths for 46 out of 48 (96%) countries for men and 14 out of 48 (29%) countries for women. Conclusion: There has been a substantial number of lung cancer deaths avoided since mortality rates peaked for many countries, though the reduction in mortality has not been observed in all countries or equally for males and females.
- Open Access
- 15 April 2026
- Published by Elsevier in JTO Clinical and Research Reports
- Vol. 7 (6) , 101002
Brief Report: Impact of PLCOm2012 Ethnicity Model Variations on Eligibility for the Alberta Lung Cancer Screening Program
- 15 April 2026
- Published by Elsevier in JTO Clinical and Research Reports
- Vol. 7 (6) , 101002
Open AccessBrief Report: Impact of PLCOm2012 Ethnicity Model Variations on Eligibility for the Alberta Lung Cancer Screening Program
- Open Access
- 22 July 2025
- Published by Elsevier in CHEST Pulmonary
- Vol. 3 (4) , 100197
Concordance of a Web-based Lung Cancer Risk Self-Assessment Tool With Nursing Risk Assessment
- 22 July 2025
- Published by Elsevier in CHEST Pulmonary
- Vol. 3 (4) , 100197
Open AccessConcordance of a Web-based Lung Cancer Risk Self-Assessment Tool With Nursing Risk Assessment
- 17 January 2025
- Published by Wolters Kluwer Health in Journal of Bronchology & Interventional Pulmonology
- Vol. 32 (2)
Use of Narrow Band Imaging to Guide Endobronchial Biopsy for Suspected Sarcoidosis
Background: Diagnosis of sarcoidosis often involves endobronchial biopsy (EBB), but studies have shown varying yields for EBB in suspected sarcoidosis, partly due to differences in identifying abnormal mucosa under white light (WL). Narrow band imaging (NBI) may assist in the visualization of abnormal mucosa, but its role in sarcoidosis remains to be characterized. Methods: Individuals referred for suspected sarcoidosis were considered for enrollment. Bronchoscopy with both WL and NBI was conducted, followed by EBB. The main objectives were to characterize NBI abnormalities in this patient population and determine the incremental yield of NBI-directed EBB. Results: In our cohort of 100 suspected sarcoidosis patients (66% male, median age 42), 88 were diagnosed with sarcoidosis, through cytopathology (n=78) or clinical evaluation (n=10). NBI high-grade lesions were more common than WL high-grade lesions (58% vs. 27%, difference 31%, 95% CI 18.3-42.5% PPP=0.366]. EBB positivity and false-negative EBUS-TBNA were more common in patients with Scadding stage 2 or greater, suggesting that the chest radiography stage may help select patients more likely to benefit from adjunctive EBB. Conclusion: NBI abnormalities are common in patients with sarcoidosis, but unlike WL abnormalities, do not predict the finding of granulomatous inflammation on EBB. The chest radiography stage may be useful to identify patients more likely to benefit from EBB in addition to EBUS-TBNA.
- 17 January 2025
- Published by Wolters Kluwer Health in Journal of Bronchology & Interventional Pulmonology
- Vol. 32 (2)
Use of Narrow Band Imaging to Guide Endobronchial Biopsy for Suspected Sarcoidosis
Background: Diagnosis of sarcoidosis often involves endobronchial biopsy (EBB), but studies have shown varying yields for EBB in suspected sarcoidosis, partly due to differences in identifying abnormal mucosa under white light (WL). Narrow band imaging (NBI) may assist in the visualization of abnormal mucosa, but its role in sarcoidosis remains to be characterized. Methods: Individuals referred for suspected sarcoidosis were considered for enrollment. Bronchoscopy with both WL and NBI was conducted, followed by EBB. The main objectives were to characterize NBI abnormalities in this patient population and determine the incremental yield of NBI-directed EBB. Results: In our cohort of 100 suspected sarcoidosis patients (66% male, median age 42), 88 were diagnosed with sarcoidosis, through cytopathology (n=78) or clinical evaluation (n=10). NBI high-grade lesions were more common than WL high-grade lesions (58% vs. 27%, difference 31%, 95% CI 18.3-42.5% PPP=0.366]. EBB positivity and false-negative EBUS-TBNA were more common in patients with Scadding stage 2 or greater, suggesting that the chest radiography stage may help select patients more likely to benefit from adjunctive EBB. Conclusion: NBI abnormalities are common in patients with sarcoidosis, but unlike WL abnormalities, do not predict the finding of granulomatous inflammation on EBB. The chest radiography stage may be useful to identify patients more likely to benefit from EBB in addition to EBUS-TBNA.
- Open Access
- 30 December 2024
- Published by Elsevier in Journal of Thoracic Oncology
- Vol. 20 (4) , 507-512
Brief Report: Evaluating Early Stage Lung Cancer Survival Patterns in Patients at the Upper Age Limit for Lung Cancer Screening
- 30 December 2024
- Published by Elsevier in Journal of Thoracic Oncology
- Vol. 20 (4) , 507-512
Open AccessBrief Report: Evaluating Early Stage Lung Cancer Survival Patterns in Patients at the Upper Age Limit for Lung Cancer Screening
- 29 November 2023
- Published by University of Toronto Press Inc. (UTPress) in Journal of the Association of Medical Microbiology and Infectious Disease Canada
- Vol. 8 (3) , 214-223
Randomized trial of the safety and efficacy of anti-SARS-CoV-2 mAb in the treatment of patients with nosocomial COVID-19 (CATCO-NOS)
Background: Patients with nosocomial acquisition of COVID-19 have poor outcomes but have not been included in therapeutic trials to date. Methods: A pragmatic open-label randomized controlled trial of anti-SARS-CoV-2 monoclonal antibodies (mAb) was performed in hospitalized patients with nosocomial COVID-19 infection in acute care hospitals spanning a provincial health care network. Participants within 5 days of first positive test or symptom onset were randomized to standard of care (SOC) plus a single dose intravenous mAb treatment (bamlanivimab or casirivimab/imdevimab) or SOC alone on a 2:1 basis. The primary study endpoint was the need for invasive mechanical ventilation (IMV) or inpatient mortality by day 60 after randomization. Results: Forty-six participants were enrolled from 13 hospitals between February 14 and October 8, 2021: 31 in the mAb and 15 in the SOC arm. IMV or inpatient mortality up to day 60 occurred in 4 (12.9%) participants in the mAb versus 3 in the SOC arm (20.0%), difference of −7.1% (95% CI −22.5 to 13.4, p = 0.67). The study was terminated early due to lack of equipoise as effectiveness of anti-viral therapies and mAb was published in similar high-risk patient populations. Conclusions: The trial was underpowered to detect meaningful differences given its early termination. The study does highlight the feasibility of undertaking trials in this patient population using a pragmatic approach allowing for trial participation and treatment access across a large health care network and may serve as a template for future designs.
- 29 November 2023
- Published by University of Toronto Press Inc. (UTPress) in Journal of the Association of Medical Microbiology and Infectious Disease Canada
- Vol. 8 (3) , 214-223
Randomized trial of the safety and efficacy of anti-SARS-CoV-2 mAb in the treatment of patients with nosocomial COVID-19 (CATCO-NOS)
Background: Patients with nosocomial acquisition of COVID-19 have poor outcomes but have not been included in therapeutic trials to date. Methods: A pragmatic open-label randomized controlled trial of anti-SARS-CoV-2 monoclonal antibodies (mAb) was performed in hospitalized patients with nosocomial COVID-19 infection in acute care hospitals spanning a provincial health care network. Participants within 5 days of first positive test or symptom onset were randomized to standard of care (SOC) plus a single dose intravenous mAb treatment (bamlanivimab or casirivimab/imdevimab) or SOC alone on a 2:1 basis. The primary study endpoint was the need for invasive mechanical ventilation (IMV) or inpatient mortality by day 60 after randomization. Results: Forty-six participants were enrolled from 13 hospitals between February 14 and October 8, 2021: 31 in the mAb and 15 in the SOC arm. IMV or inpatient mortality up to day 60 occurred in 4 (12.9%) participants in the mAb versus 3 in the SOC arm (20.0%), difference of −7.1% (95% CI −22.5 to 13.4, p = 0.67). The study was terminated early due to lack of equipoise as effectiveness of anti-viral therapies and mAb was published in similar high-risk patient populations. Conclusions: The trial was underpowered to detect meaningful differences given its early termination. The study does highlight the feasibility of undertaking trials in this patient population using a pragmatic approach allowing for trial participation and treatment access across a large health care network and may serve as a template for future designs.
- Open Access
- 19 October 2023
- Published by Elsevier in JTO Clinical and Research Reports
- Vol. 4 (12) , 100594
Health Care Utilization and Costs in Lung Cancer Screening Participants—A Propensity-Matched Economic Analysis
- 19 October 2023
- Published by Elsevier in JTO Clinical and Research Reports
- Vol. 4 (12) , 100594
Open AccessHealth Care Utilization and Costs in Lung Cancer Screening Participants—A Propensity-Matched Economic Analysis
- 1 June 2023
- Published by Georg Thieme Verlag KG in Seminars in Respiratory and Critical Care Medicine
- Vol. 44 (04) , 417-425
The Global Burden of Pleural Diseases
Pleural diseases include a spectrum of disorders broadly categorized into pneumothorax and pleural effusion. They often cause pain, breathlessness, cough, and reduced quality of life. The global burden of diseases reflects regional differences in conditions and exposures associated with pleural disease, such as smoking, pneumonia, tuberculosis, asbestos, cancer, and organ failure. Disease burden in high-income countries is overrepresented given the availability of data and disease burden in lower-income countries is likely underestimated. In the United States, in 2016, there were 42,215 treat-and-discharge visits to the emergency room for pleural diseases and an additional 361,270 hospitalizations, resulting in a national cost of $10.1 billion.
- 1 June 2023
- Published by Georg Thieme Verlag KG in Seminars in Respiratory and Critical Care Medicine
- Vol. 44 (04) , 417-425
The Global Burden of Pleural Diseases
Pleural diseases include a spectrum of disorders broadly categorized into pneumothorax and pleural effusion. They often cause pain, breathlessness, cough, and reduced quality of life. The global burden of diseases reflects regional differences in conditions and exposures associated with pleural disease, such as smoking, pneumonia, tuberculosis, asbestos, cancer, and organ failure. Disease burden in high-income countries is overrepresented given the availability of data and disease burden in lower-income countries is likely underestimated. In the United States, in 2016, there were 42,215 treat-and-discharge visits to the emergency room for pleural diseases and an additional 361,270 hospitalizations, resulting in a national cost of $10.1 billion.